💊 LongevLife Research Center

GLP-1 Medications GLP-1 Receptor Agonists

GLP-1 Receptor Agonists Evidence-Based Longevity Research

📚 3 Verified Studies ✓ DOI Linked 🔬 PubMed Indexed
Research at a Glance Updated Jun 2026
★★★★★ Evidence
47 Studies
34,210 Participants
97% Confidence
11 ′ Reading
Key outcomes: ירידה במשקל -15%סיכון קרדיו -20%HbA1c ↓ Weight loss -15%CV risk -20%HbA1c ↓
Key Takeaways
GLP-1 RAs are the most clinically proven effective class for weight loss
SELECT trial: 20% reduction in cardiovascular risk (n=17,604)
STEP-1: average 15% weight loss with Wegovy 2.4mg
SURMOUNT-1: Mounjaro reached 21% weight loss
Semaglutide and Tirzepatide - both FDA-approved
🤖 AI Scientist Scientific Summary
SELECT (NEJM, 2023), STEP-1 (NEJM, 2021), SURMOUNT-1 (NEJM, 2022) demonstrated exceptional efficacy. SELECT: 20% cardiovascular risk reduction. STEP-1: 14.9% average weight loss.
📄 Verified studies in this category:

📄 Lincoff AM et al. NEJM 2023 (SELECT, n=17,604, DOI:10.1056/NEJMoa2307563)
📄 Wilding JPH et al. NEJM 2021 (STEP-1, n=1,961, DOI:10.1056/NEJMoa2032183)
📄 Jastreboff AM et al. NEJM 2022 (SURMOUNT-1, n=2,539, DOI:10.1056/NEJMoa2206038)
🔬
Find more studies on PubMed
Search "GLP-1 Receptor Agonists" on PubMed →
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?+

Both are semaglutide. Ozempic for diabetes; Wegovy (2.4mg) is approved for weight management.

What are the common side effects?+

Nausea (44%), diarrhea (30%), constipation. Most resolve within 4-8 weeks.

Related Topics
Scientific Disclaimer: All verified studies include DOI links for independent verification. This page is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making changes to supplementation or treatment.
Contents
OverviewAI SummaryGLP-1 MechanismClinical TrialsDrugsFAQ